Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FibroGen Inc.

www.fibrogen.com

Latest From FibroGen Inc.

AstraZeneca's Dobber On Ramping In Renal, Expanding In CV And Business Development

Biopharmaceuticals President Ruud Dobber talked to Scrip about the launches of Lokelma and roxadustat in kidney disease, building with a high bar in cardiovascular disease and expanding in cell and gene therapy.

Business Strategies Leadership

Keeping Track: Year-End Submissions Rush Brings Seven Novel Agents To US FDA

Highlights of year-end application submissions including candidates from AstraZeneca, BioMarin, Lilly, MorphoSys, and Seattle Genetics.

Drug Review Review Pathway

Astellas Beats Rivals To Japan HIF-PHI Market As Roxadustat Launched

Astellas becomes first to market in Japan in new class of oral anemia drugs, beating multiple rivals in a sector set to see strong growth but also fierce competition.

Japan Launches

Clear Path For AstraZeneca’s Roxadustat After Reassuring Safety Data

Strong results in non-dialysis patients are a particular boost for AZ and its partner, Fibrogen.

Clinical Trials Research & Development
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Hepatic (Liver)
  • Musculoskeletal & Connective Tissue Disorders
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • FibroGen Inc.
  • Senior Management
  • Enrique Conterno, CEO
    Pat Cotroneo, VP, Fin. & CFO
    David M Dimmick, MD, VP, Quality
    R. Wayne Frost, VP, RA
    Elias Kouchakji, MD, VP, Clinical Dev and Drug Safety
    AI Lin, MD, PhD, VP, Drug Dev.
    Peony K Yu, CMO
  • Contact Info
  • FibroGen Inc.
    Phone: (415) 978-1200
    409 Illinois St.
    San Francisco, CA 94158
    USA
UsernamePublicRestriction

Register